Dermatology 2013

Notes: Safizadeh, H

Nakhaee, N

Shamsi-Meymandi, S

Pourdamghan, N

Basra, M K A

eng

Research Support, Non-U.S. Gov’t

Validation Studies

Netherlands

2013/09/21 06:00

Qual Life Res. 2014 Apr;23(3):869-75. doi: 10.1007/s11136-013-0514-6. Epub 2013 Sep 20.

URL: http://www.ncbi.nlm.nih.gov/pubmed/24052325

Author Address: Research Center for Social Determinants of Health, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.

 

 

Reference Type:  Journal Article

Record Number: 4428Author: Saka, B., Mouhari-Toure, A., Wateba, I. M., Akakpo, S., Kombate, K., Balaka, A., Sogan, A., Afolabi, K. O., Pitche, P. and Tchangai-Walla, K.

Year: 2013

Title: [AIDS related Kaposi sarcoma: 103 cases in dermatology in Lome (Togo)]

Journal: Med Sante Trop

Volume: 23

Issue: 1

Pages: 109-11

Date: Jan-Mar

Short Title: [AIDS related Kaposi sarcoma: 103 cases in dermatology in Lome (Togo)]

Alternate Journal: Medecine et sante tropicales

ISSN: 2261-2211 (Electronic)

DOI: 10.1684/mst.2013.0145

Original Publication: Maladie de Kaposi associee au VIH : 103 observations en dermatologie a Lome (Togo).

Accession Number: 23692859

Keywords: *AIDS-Related Opportunistic Infections/drug therapy/epidemiology

Adolescent

Adult

Aged

Child

Child, Preschool

Female

Humans

Male

Middle Aged

Retrospective Studies

*Sarcoma, Kaposi/drug therapy/epidemiology

Togo/epidemiology

Young Adult

Abstract: OBJECTIVE: The purpose of this study was to describe the epidemiological and clinical profile and the treatment and natural history of AIDS-related Kaposi sarcoma in 3 major dermatology departments in Lome (Togo). PATIENTS AND METHOD: This retrospective, descriptive study was based on the records of patients with AIDS-related Kaposi sarcoma from January 2005 through October 2011. RESULTS: During the study period, 157 patients were treated in the dermatology departments for Kaposi sarcoma. HIV serology was positive for 103 (89.6%) of the 115 patients tested. Seventy-nine patients were known to be HIV-positive before the consultation, while Kaposi sarcoma was the circumstance of discovery of the HIV infection for 24. The average age of the 103 patients was 36.7+/-14.9 years and the sex-ratio (M/F) was 1.1. The main locations of the lesions were the lower limbs (n = 76), mucosa (n = 53), trunk (n = 38) and upper limbs (n = 17). The average CD4-cell count was 226+/-168 cells/mm(3). The main antiretroviral protocol used was stavudine/lamivudine/nevirapine (70 cases). Besides the antiretroviral treatment, chemotherapy was prescribed, with vinblastine for 17 patients, bleomycin for 5, and doxorubicin for one. For financial reasons, 80 other patients did not receive chemotherapy and were lost to follow-up after an average duration of 3 months. At 5 months, the rate of complete remission was 21.1%, partial remission 21.1%, and failure 57.8%. Side effects were dominated by hematologic and nervous complications. CONCLUSION: Our study highlighted a high prevalence of AIDS-related Kaposi sarcoma in dermatology departments in Lome, with a tendency to gender equality. It also shows the difficulties of access to chemotherapy for most patients and the poor efficacy of chemotherapy.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295